Regional Analysis

Global HER-2 Negative Breast Cancer Market: Regional Insights

Based on geography, the global HER-2 negative breast cancer market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Among regions, North America is expected to gain highest share in the market over the forecast period owing to the increasing growing burden of breast cancer, increase in demand for safe and effective treatment, and increase in research and development in the region. For instance, HER2-negative negative breast cancer means that the cancerous cells do not contain high levels of the protein HER2. In April 2021, the Food and Drug Administration (FDA) granted regular approval to sacituzumab govitecan (Trodelvy) for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC).

Europe and Asia Pacific are also expected to witness robust growth in the global HER-2 negative breast cancer market due to the rise in incidence of breast cancer, increase in demand for safe and effective treatment, and introduction of novel drugs or therapies in these regions. For instance, in January 2023, Daiichi Sankyo and AstraZeneca’s ENHERTU (trastuzumab deruxtecan) approved in the European Union (EU) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2 breast cancer who have received prior chemotherapy. This in turn is driving the growth of the HER-2 negative breast cancer market in Europe.

Figure 1. Global HER-2 Negative Breast Cancer Market Share (%), by Region, 2023